Wall Street Uneasy as Jerome Powell Threat, Iran Unrest Pressure Market
Amid legal pressure on the Fed Chair and geopolitical heat, biotech remains a bright spot. Here's my game plan and the specific biotech plays I'm focused on.
You're reading 0 of 1 free page.
Register to read more or Unlock Pro — 50% Off Ends Soon
Two events are putting pressure on the market early Monday morning. The first and most significant is news that federal prosecutors are considering criminal charges against Fed Chair Jerome Powell. This stems from testimony last year dealing with a central bank building renovation that has gone far over budget. Powell called the move a pretext for the real issue: interest rate policy and the independence of the Federal Reserve.
While many on Wall Street believe there is a valid argument for interest rate cuts, this tactic of using criminal charges seems to be a bridge too far. Threatening Powell in this manner sends a message to future Fed leaders that they will not be able to act independently. Wall Street simply does not like this approach to a policy disagreement.
Geopolitical Heat in the Middle East
The second issue is the growing unrest in Iran, which may topple the government. The Trump administration is scheduled to meet on Tuesday to discuss the actions the U.S. will take to support the popular uprising. Determining the extent of the unrest is difficult right now because the country has cut off reporting and internet access.
Iran will obviously affect the oil market, but there will also be other ramifications for political and economic relationships. While it is generally believed that an overthrow of the current government is a positive, it will not be easy or simple.
Biotech Remains the Bright Spot
Another event this week of interest to traders is the 44th Annual JPMorgan Healthcare Conference in San Francisco. This preeminent event for the biotechnology sector usually produces significant announcements.
Biotechnology is my top sector pick for 2026. One of the main reasons is the looming patent cliff, during which pharmaceutical companies are estimated to lose $150 billion in revenue over the next several years.
This is triggering a wave of acquisitions by big-cap pharmaceutical companies that want to broaden their product offerings. Just this morning, a French publication reported that Eli Lilly (LLY) is interested in acquiring Abivax SA (ABVX) at a substantially higher price, and the stock is already up 25% on the news.
Regulatory Winds Are Shifting
The FDA also issued a new policy framework on Sunday, entitled "Flexible Requirements for Cell and Gene Therapies to Advance Innovation." This is a major positive and addresses concerns that have been building due to personnel changes at the agency. I will discuss this in more depth later, but it provides much-needed clarity for the group.
Market Action and Game Plan
Precious metals are moving higher as a safe-haven play amid tensions in Iran and rising interest rates. Overseas markets showed strength, with Chinese and Japanese stocks sharply higher and record volume in mainland China.
My game plan is to look for short-term trading opportunities caused by the early volatility. I do not believe we are seeing a major top at this point, and view pullbacks as opportunities rather than a warning. I am focused specifically on gene therapy plays in biotechnology.
At the time of publication, Rev Shark was long ABVX.
